TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257436

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT-D
Description: Left Ventricular MultiSite Pacing
Study: NCT05387616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.
Study: NCT01245101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
Study: NCT02280330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP group
Description: MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
Study: NCT03971331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAC catheter and critical care ultrasound examination
Description: Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
Study: NCT01753882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Agent + training vs Placebo + training

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Agent + training vs Placebo + training
Study: NCT03286920

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral nutrition supplement
Description: As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Tube feeding nutrition supplement
Description: As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
Study: NCT01616043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glyaderm
Description: acellular dermis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: STSG
Description: autologous split skin only
Study: NCT04396652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block and IPACK block group
Description: Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
Study: NCT01408706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Air tip
Description: Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiadyne Immobilizer
Description: Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
Study: NCT02447419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg will be administered orally daily
Study: NCT04092738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk@WorkApp-Diab
Description: The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
Study: NCT03798743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Docetaxel
Description: Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
Study: NCT03772808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycocomfort
Description: Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
Study: NCT04151069

Intervention type: OTHER
Intervention: Procedure A
Description: Up-dosing nut drink at home

Intervention type: OTHER
Intervention: Procedure B
Description: Up-dosing nut drink at the hospital

Intervention type: OTHER
Intervention: Control group
Description: Strict avoidance of tree nut consumption
Study: NCT03022006

Intervention type: DRUG
Group type: OTHER
Intervention: elbasvir, grazoprevir
Study: NCT01766362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRPC using Pascal laser

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PRPC using Pascal laser
Study: NCT02979782

Intervention type: PROCEDURE
Intervention: Endo-CABG
Description: minimal invasive cardiac intervention

Intervention type: PROCEDURE
Intervention: PCI
Description: stenting procedure
Study: NCT04157010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT03444844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 P16-093 PET/CT scan
Description: IV injection followed by PET/CT scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 P16-093 PET/CT scan
Description: IV injection followed by PET/CT scanning
Study: NCT02869789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with Ipilimumab
Description: Specified dose on specified days
Study: NCT00230048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computer-delivered intervention
Description: Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
Study: NCT03628651

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: HCC subjects will have one blood sample collected.

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
Study: NCT00575354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: 3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
Study: NCT02909010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS™ Brain Monitoring System
Description: The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RASS
Description: control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
Study: NCT01460732

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Pressure Monitoring
Description: Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
Study: NCT02911649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Garmin Vivosmart
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Garmin Vivosmart
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Study: NCT02504983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
Study: NCT02911649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Educational Group
Description: A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Educational Group
Description: A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - FitBit Alta
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - FitBit Alta
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Polar Loop 2
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Polar Loop 2
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Study: NCT00842634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN modified T cells
Description: A single infusion of 5-10 billion ZFN Modified CD4+ T Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN modified T cells
Description: A single infusion of 5-10 billion ZFN Modified CD4+ T Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN modified T cells
Description: A single infusion of 5-10 billion ZFN Modified CD4+ T Cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruption
Description: Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
Study: NCT04458519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiorinse
Description: Nasal irrigations with probiotic twice-daily for a period of fourteen days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Nasal irrigations with saline-only twice-daily for a period of fourteen days
Study: NCT04623866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huaiqinhuang
Description: Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan granules 80mg/1.73m2 based qd 24 weeks
Study: NCT03851263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
Study: NCT04283786

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
Study: NCT01564004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis or neuro-linguistic programming
Description: 20 minutes tape recording intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical hypnosis or neuro-linguistic programming
Description: 20 minutes tape recording intervention
Study: NCT04823780

Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient solution
Description: For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
Study: NCT04620577

Intervention type: OTHER
Intervention: antibiotic
Description: normal saline

Intervention type: OTHER
Intervention: antibiotic
Description: normal saline
Study: NCT01012427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous cryoablation
Description: All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase \> 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
Study: NCT01500798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg bardoxolone methyl
Description: 20 mg, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study: NCT01644721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Early measles vaccine
Description: Standard Edmonston-Zagreb measles vaccine
Study: NCT03511677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Customized insole

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Insole
Description: Placebo flat insole
Study: NCT03352076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Danazol
Description: Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Danatrol
Description: Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
Study: NCT02991365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal insulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo spray
Study: NCT02127658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene education
Description: Participants will receive specific hygiene instructions according to existing recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
Study: NCT03159598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Glu
Description: Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Glu
Description: Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Study: NCT03101891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial amnioinfusions with isotonic fluid
Description: Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
Study: NCT03159598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
Study: NCT02541617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Programming by community Neurologist
Description: Deep Brain stimulator with be programmed by a community Neurologist
Study: NCT03101891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal needle
Description: A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic fluid
Description: Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.